Effects of atmospheric-pressure non-thermal bio-compatible plasma and plasma activated nitric oxide water on cervical cancer cells.
Effects of atmospheric-pressure non-thermal bio-compatible plasma and plasma activated nitric oxide water on cervical cancer cells.
复制标题
DOI：
10.1038/srep45781
复制
发表时间：
2017-03-31
影响因子：
4.6
通讯作者：
Han I
中科院分区：
文献类型：
--
作者：
Li Y;Ho Kang M;Sup Uhm H;Joon Lee G;Ha Choi E;Han I
大气压非热生物相容等离子体是一种部分电离的气体与带电粒子。先前的研究表明，介质阻挡放电（DBD）等离子体可以诱导各种癌细胞的凋亡，特别是证明了癌细胞相对于正常细胞的选择性细胞毒性。因此，DBD等离子体可以被认为是一种潜在的用于临床应用的癌症治疗方法。我们以前开发了一种微波射流等离子体系统，产生一氧化氮，称为一氧化氮等离子体活化水（NO-PAW）。在这项研究中，我们探讨了NO-PAW对宫颈癌细胞系的影响，与DBD血浆相比。细胞毒性实验结果表明，DBD处理HeLa细胞4 min，NO-PAW浓度为7 μM时，其IC 60值接近。在细胞凋亡实验中，DBD处理4 min可诱导7%的细胞凋亡，而7 μM NO-PAW处理4 min可诱导18%的细胞凋亡。此外，我们假设DBD等离子体和NO-PAW都可以通过促进细胞内活性氧和氮（RONS）的积累来诱导HeLa细胞凋亡。尽管仍需要进一步详细了解分子信号通路，但DBD和NO-PAW可能成为有效和安全的癌症治疗临床试验的有前景的应用。
Atmospheric-pressure non-thermal bio-compatible plasma is a partially ionized gas with electrically charged particles. Previous studies demonstrated that dielectric barrier discharge (DBD) plasma could induce apoptosis of various cancer cells, in particular demonstrating the selective cytotoxicity of cancer cells over normal cells. Therefore, DBD plasma can be considered as a potential cancer treatment method for clinical applications. We previously developed a microwave jet plasma system, producing nitric oxide called nitric oxide-plasma activated water (NO-PAW). In this study, we explored the effects of NO-PAW on a cervical cancer cell line, in comparison with DBD plasma. The cytotoxicity results showed that the treatment of HeLa cell with DBD for 4 minutes and 7 μM concentration of NO-PAW could reach almost IC60. For the apoptosis assay, 4 minutes treatment of DBD could induce 7% apoptotic effect, whereas 7 μM NO-PAW could induce 18% apoptotic effect. In addition, we assumed that both DBD plasma and NO-PAW could induce HeLa cell apoptosis by facilitating an accumulation of intracellular reactive oxygen and nitrogen species (RONS). Although further detail on the molecular signal pathway is still needed, DBD and NO-PAW could become promising applications for effective and safe clinical trials for cancer therapy.